Validation of IMACS and PRINTO Definitions of Improvement
Lisa Rider, NIEHS, NIH
Natural history study
Types & Number of IIM Studied:
Adult and Juvenile Dermatomyositis, Polymyositis, Overlap Myositis, Inclusion Body Myositis (> 100 patients)
Probable or definite Bohan and Peter criteria; Griggs et al. 1995 Annals of Neurology Inclusion Body Myositis criteria
IMACS Core Set Measures Included:
All: Physician and Patient Global Activity and Damage Assessments, Manual Muscle Testing, Childhood Myositis Assessment Scale, [Childhood] Health Assessment Questionnaire, muscle enzymes, Myositis Disease Activity Assessment Tool, Myositis Damage Index; Health Related Quality of Life by SF-36 and Child Health Questionnaire
Other Measures Included:
Disease Activity Score, demographic and treatment data, extended measures
IMACS and PRINTO Definitions of Improvement
Baseline and 6 - 9 month evaluation. Open
Ongoing. Extramural centers may apply for enrollment into IMACS registry by obtaining local IRB approval of this protocol.
Lisa Rider, M.D.
Group Deputy Chief
Environmental Autoimmunity Group
Frederick W. Miller, M.D., Ph.D.
Deputy Chief, Clinical Research Branch and Principal Investigator
Return to Studies in the Repository listing